Forget a Cash ISA! I’d buy these 2 FTSE 250 dividend growth stocks right now

These two FTSE 250 (INDEXFTSE:MCX) shares could generate significantly higher income returns than a Cash ISA, in my opinion.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

While investing in FTSE 250 dividend shares carries greater risks than having a Cash ISA, doing so could certainly lead to higher returns in the long run. Cash ISAs generally offer income returns that are 1.5% at best, which is below the rate of inflation. However, within the FTSE 250 it’s possible to generate a significantly higher income return, as well as benefit from above-inflation growth in dividends.

With that in mind, here are two mid-cap stocks that appear to offer a potent mix of a relatively appealing income return, as well as the potential for capital growth over the long run.

Games Workshop

Designer, manufacturer and retailer of miniature wargaming products, Games Workshop (LSE: GAW), released an encouraging trading update on Friday. The company has seen the momentum in the earlier part of 2019 continue through into the last couple of months. This means sales for the 2019 financial year are expected to hit £254m, with profit before tax due to be at least £80m.

Should you invest £1,000 in Crispr Therapeutics right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Crispr Therapeutics made the list?

See the 6 stocks

During the 2019 financial year, which ended 2 June, the company paid a dividend of 155p per share, that’s an increase of 23% on fiscal 2018. It means the company yielded 3.3%.

Since it has an ongoing policy of distributing surplus cash to shareholders when available, its continued strong performance suggests further improvements to its dividend payments may be ahead over the long run.

With Games Workshop having a strong position within what remains a fast-growing market, it could generate impressive returns over the coming years. Although further pressure on consumer confidence may affect its performance in the near term, it could deliver a rising dividend in the long run.

Redrow

While the housebuilding sector has been highly unpopular among investors in the last few years, the performance of Redrow (LSE: RDW) has been impressive. The FTSE 250-listed housebuilder has posted double-digit earnings growth in each of the last five years, which suggests its business model is sound.

Looking ahead, demand for new homes is expected to remain high. A supply shortage, the wide availability of finance through mortgages, and the government’s Help to Buy scheme could mean the sector is set for a period of further growth.

Certainly, there are a variety of political and economic risks ahead. But with Redrow trading on a price-to-earnings (P/E) ratio of 6.2, it appears to offer a wide margin of safety. Furthermore, its dividend yield of 5.3% is covered three times by profit, which also suggests it’s highly sustainable.

Although the housebuilding sector may remain unpopular among investors over the short run, in the long term companies such as Redrow could offer high income returns and the prospect of significant capital growth. As such, I think now could be a good time to buy a slice of the business.

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in Crispr Therapeutics right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Crispr Therapeutics made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of Redrow. The Motley Fool UK has recommended Redrow. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Dividend Shares

How a stock market crash could boost investors’ passive income by over 40%

Jon Smith explains how a continued fall in the stock market isn't always a bad thing, especially when it comes…

Read more »

Investing Articles

If an investor put £10k into Greggs shares one month ago, here’s what they’d have today

Greggs shares have had a tough year but Harvey Jones says they're notably cheaper as a result, while the dividend…

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

The Phoenix share price jumps 7.5% on today’s results, but still yields a stunning 9.4%!

Harvey Jones put his faith in the Phoenix share price and this morning was rewarded with a 7.5% jump on…

Read more »

Investing Articles

What’s been going on with the Barclays share price?

The rising Barclays share price reflects confidence in management’s strategy to improve business performance and enhance shareholder returns.

Read more »

Investing Articles

Prediction: in 1 year, the IAG share price could reach as high as…

The IAG share price has almost doubled in the last 12 months, but can this momentum continue in 2025? Zaven…

Read more »

Investing Articles

Prediction: in 12 months, here’s where the Glencore share price could be…

The performance of Glencore’s share price has been lacklustre, to say the least. But could all that change over the…

Read more »

Investing Articles

See how much an investor needs in their ISA to earn a £499 monthly second income

Harvey Jones crunches the numbers to show how it's possible to build a long-term second income by investing in a…

Read more »

Investing Articles

I’m considering buying more of this struggling FTSE 100 stock

This FTSE 100 stock hasn't exactly set our writer's portfolio on fire during the time he's owned it. But Paul…

Read more »